Anzeige
Mehr »
Dienstag, 14.07.2026 - Börsentäglich über 12.000 News
Time to Buy! Diese drei Kräfte treiben die Tiefsee-Exploration massiv an
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A421M8 | ISIN: US98422T2096 | Ticker-Symbol:
NASDAQ
13.07.26 | 21:34
9,000 US-Dollar
-2,60 % -0,240
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XILIO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
XILIO THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur XILIO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.07.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1
29.06.Xilio Therapeutics beruft Ben Harshbarger zum neuen Chief Legal Officer3
29.06.Xilio Therapeutics appoints Ben Harshbarger as chief legal officer4
29.06.Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer626WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people...
► Artikel lesen
12.06.Xilio Therapeutics, Inc. - 8-K, Current Report1
12.05.Xilio Therapeutics reports Q1 results1
12.05.Xilio Therapeutics, Inc.: Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates531On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data...
► Artikel lesen
12.05.Xilio Therapeutics, Inc. - 10-Q, Quarterly Report2
XILIO THERAPEUTICS Aktie jetzt für 0€ handeln
12.05.Xilio Therapeutics, Inc. - 8-K, Current Report1
07.05.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1
17.04.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.21
16.04.Xilio Therapeutics appoints Cheryl Blanchard to board1
16.04.Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors1
16.04.Xilio Therapeutics, Inc. - 8-K, Current Report-
03.04.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2
23.03.Xilio plans mid-2026 IND filing for cancer therapy XTX5012
23.03.Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
23.03.Xilio plant IND-Antrag für Krebstherapie XTX501 für Mitte 20262
23.03.Xilio Therapeutics, Inc. - 10-K, Annual Report3
23.03.Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results400XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class...
► Artikel lesen
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1